ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Ann Thorac Surg 2008;85:265-272. doi:10.1016/j.athoracsur.2007.07.042
© 2008 The Society of Thoracic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Harvey I. Pass
Right arrow Permission Requests
Google Scholar
Right arrow Articles by Pass, H. I.
Right arrow Articles by Allard, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pass, H. I.
Right arrow Articles by Allard, J.
Related Collections
Right arrow Pleura

Original Articles: General Thoracic

Soluble Mesothelin-Related Peptide Level Elevation in Mesothelioma Serum and Pleural Effusions

Harvey I. Pass, MDa,*, Anil Wali, PhDb, Naimei Tang, PhDb, Alla Ivanova, PhDa, Sergey Ivanov, PhDa, Michael Harbut, MDb, Michele Carbone, MD, PhDc, Jeffrey Allard, PhDd

a Department of Cardiothoracic Surgery, Division of Thoracic Surgery, New York University School of Medicine, New York, New York
b Karmanos Cancer Institute, Detroit, Michigan
c Cancer Research Center of Hawaii, Honolulu, Hawaii
d Fujirebio Diagnostics Inc, Malvern, Pennsylvania

Accepted for publication July 16, 2007.

* Address correspondence to Dr Pass, Department of Cardiothoracic Surgery, Division of Thoracic Surgery, NYU School of Medicine, 530 First Avenue, 9V, New York, NY 10016 (Email: harvey.pass{at}med.nyu.edu).

Presented at the Forty-third Annual Meeting of The Society of Thoracic Surgeons, San Diego, CA, Jan 29–31, 2007.

Background: Soluble mesothelin-related peptide (SMRP) is a potential marker for malignant pleural mesothelioma (MPM), which may be useful for screening high-risk asbestos-exposed individuals.

Methods: We evaluated SMRP in serum from MPM patients (n = 90), lung cancer patients (n = 170), age and tobacco-matched asbestos-exposed individuals (n = 66), and in MPM pleural effusions (n = 45), benign effusions (n = 30), and non-MPM effusions (n = 20) using the MesoMark enzyme-linked immunosorbent assay kit (Fujirebio Diagnostics, Malvern, PA). Receiver operating characteristic (ROC) curves were used to define true and false positive rates at various cutoffs.

Results: Mean serum SMRP levels were higher in MPM compared with lung cancer (5.67 ± 0.82 nM [mean ± standard error of the mean vs 1.99 ± 0.43 nM, p < 0.001), and stage I MPM SMRP levels (n = 12; 2.09 ± 0.41 nM) were significantly higher than those in asbestos-exposed individuals (0.99 ± 0.09 nM, p = 0.02, respectively). Stage 2 to 4 SMRP serum levels were significantly higher than those for stage 1 MPM. The area under the ROC curve for serum SMRP was 0.81 for differentiating MPM and asbestos-exposed individuals; cutoff = 1.9 nM (sensitivity = 60%, specificity = 89%). The MPM pleural effusion SMRP was significantly higher than benign or other non-MPM pleural effusions (65.57 ± 11.33 nM vs 27.46 ± 11.25 nM [p = 0.003] and 18.99 ± 7.48 nM [p = 0.044], respectively).

Conclusions: These data support SMRP as a promising marker for MPM in both serum and pleural effusion fluid, and justify prospective screening studies of SMRP in combination with other markers for screening of asbestos-exposed cohorts.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 by The Society of Thoracic Surgeons.